Meike L Schipper1, Michael L Goris, Sanjiv S Gambhir. 1. Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Palo Alto, CA 94305-5427, USA.
Abstract
PURPOSE: Evaluation of selective killing of Herpes Simplex Virus 1 thymidine kinase (HSV1-tk) expressing tumors by radiolabeled (131)I-fialuridine (FIAU), and of synergy between (131)I-FIAU and Ganciclovir (GCV). PROCEDURES: HSV1-tk-expressing cell lines and parental cell lines were exposed to (131)I-FIAU alone, GCV alone, or combinations. Activity and concentration were varied widely, concurrent and sequential administrations tested, and dose rate effects were studied. RESULTS: HSV1-tk-expressing cells accumulated up to 15.7-fold more (131)I-FIAU, were growth inhibited by 2 muCi/ml, or 5 muCi/ml (131)I-FIAU, and were inhibited by two log orders lower concentrations of GCV than parental cells. However, no synergy or additive effect was observed. Dose rate variations, or sequential treatment, did not alter outcome. CONCLUSION: Radioisotope therapy of HSV1-tk-expressing tumor cells with (131)I-FIAU is reported for the first time. Lack of synergy between (131)I-FIAU and GCV does not warrant further investigation of combination treatment with the two agents.
PURPOSE: Evaluation of selective killing of Herpes Simplex Virus 1 thymidine kinase (HSV1-tk) expressing tumors by radiolabeled (131)I-fialuridine (FIAU), and of synergy between (131)I-FIAU and Ganciclovir (GCV). PROCEDURES: HSV1-tk-expressing cell lines and parental cell lines were exposed to (131)I-FIAU alone, GCV alone, or combinations. Activity and concentration were varied widely, concurrent and sequential administrations tested, and dose rate effects were studied. RESULTS: HSV1-tk-expressing cells accumulated up to 15.7-fold more (131)I-FIAU, were growth inhibited by 2 muCi/ml, or 5 muCi/ml (131)I-FIAU, and were inhibited by two log orders lower concentrations of GCV than parental cells. However, no synergy or additive effect was observed. Dose rate variations, or sequential treatment, did not alter outcome. CONCLUSION: Radioisotope therapy of HSV1-tk-expressing tumor cells with (131)I-FIAU is reported for the first time. Lack of synergy between (131)I-FIAU and GCV does not warrant further investigation of combination treatment with the two agents.
Authors: Anne Rixt Buursma; Vera Rutgers; Geke A P Hospers; Nanno H Mulder; Willem Vaalburg; Erik F J de Vries Journal: Nucl Med Commun Date: 2006-01 Impact factor: 1.690
Authors: M Quigg; R J Mairs; S M Brown; J Harland; P Dunn; R Rampling; A Livingstone; L Wilson; M Boyd Journal: Med Chem Date: 2005-09 Impact factor: 2.745
Authors: Iván Peñuelas; Guillermo Mazzolini; José F Boán; Bruno Sangro; Josep Martí-Climent; María Ruiz; Juan Ruiz; Nagichettiar Satyamurthy; Cheng Qian; Jorge R Barrio; Michael E Phelps; José A Richter; Sanjiv S Gambhir; Jesús Prieto Journal: Gastroenterology Date: 2005-06 Impact factor: 22.682
Authors: T M Behr; E Wulst; S Radetzky; R D Blumenthal; R M Dunn; S Gratz; M Rave-Fränk; H Schmidberger; F Raue; W Becker Journal: Cancer Res Date: 1997-12-01 Impact factor: 12.701
Authors: D Klatzmann; C A Valéry; G Bensimon; B Marro; O Boyer; K Mokhtari; B Diquet; J L Salzmann; J Philippon Journal: Hum Gene Ther Date: 1998-11-20 Impact factor: 5.695
Authors: S S Gambhir; E Bauer; M E Black; Q Liang; M S Kokoris; J R Barrio; M Iyer; M Namavari; M E Phelps; H R Herschman Journal: Proc Natl Acad Sci U S A Date: 2000-03-14 Impact factor: 11.205
Authors: De-Xue Fu; Yvette Tanhehco; Jianmeng Chen; Catherine A Foss; James J Fox; Ja-Mun Chong; Robert F Hobbs; Masashi Fukayama; George Sgouros; Jeanne Kowalski; Martin G Pomper; Richard F Ambinder Journal: Nat Med Date: 2008-09-07 Impact factor: 53.440
Authors: Marie-France Penet; Zhihang Chen; Cong Li; Paul T Winnard; Zaver M Bhujwalla Journal: Drug Deliv Transl Res Date: 2012-02-01 Impact factor: 4.617